ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reddel, H.
Right arrow Articles by Woolcock, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reddel, H.
Right arrow Articles by Woolcock, A.
Eur Respir J 2000; 16: 226-235
Copyright © ERS Journals Ltd 2000


Clinical Trial

Optimal asthma control, starting with high doses of inhaled budesonide

HK Reddel, CR Jenkins, GB Marks, SI Ware, W Xuan, CM Salome, CA Badcock, and AJ Woolcock

The aim of this study was to determine whether outcomes in poorly controlled asthma can be further improved with a starting dose of inhaled budesonide higher than that recommended in international guidelines. The study had a parallel-group design and included 61 subjects with poorly controlled asthma, randomized to receive 3,200 microg or 1,600 microg budesonide daily by Turbuhaler for 8 weeks (double-blind), then 1,600 microg x day(-1) for 8 weeks (single-blind), followed by 14 months of open-label budesonide dose down-titration using a novel algorithm, with a written asthma crisis plan based on electronic peak expiratory flow monitoring. The primary outcome variable for weeks 1-16 was change in airway hyperresponsiveness (AHR), and, for the open-label phase, mean daily budesonide dose. By week 16, there were large changes from baseline in all outcomes, with no significant differences between the 3,200- and 1,600-microg x day(-1) starting dose groups (AHR increased by 3.2 versus 3.0 doubling doses, p=0.7; morning peak flow increased by 134 versus 127 L x min(-1), p=0.8). Subjects starting with 3,200 microg x day(-1) were 3.8 times more likely to achieve AHR within the normal range, as defined by a provocative dose of histamine causing a 20% fall in forced expiratory volume in one second (PD20) of > or = 3.92 micromol by week 16 (p=0.03) [corrected]. During dose titration, there was no significant difference in mean budesonide dose (1,327 versus 1,325 microg x day(-1), p>0.3). Optimal asthma control was achieved in the majority of subjects (at completion/withdrawal: median symptoms 0.0 days x week(-1), beta2-agonist use 0.2 occasions x day(-1), and PD20 2.4 micromol). In subjects with poorly controlled asthma, a starting dose of 1,600 microg x day(-1) budesonide was sufficient to lead to optimal control in most subjects. The high degree of control achieved, compared with previous studies, warrants further investigation.


This article has been cited by other articles:


Home page
ERRHome page
M. Gaga, E. Zervas, and P. Chanez
Update on severe asthma: what we know and what we need
Eur. Respir. Rev., June 1, 2009; 18(112): 58 - 65.
[Full Text] [PDF]


Home page
ChestHome page
P. M. O'Byrne, I. P. Naya, A. Kallen, D. S. Postma, and P. J. Barnes
Increasing Doses of Inhaled Corticosteroids Compared to Adding Long-Acting Inhaled {beta}2-Agonists in Achieving Asthma Control
Chest, December 1, 2008; 134(6): 1192 - 1199.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D. R. Taylor, E. D. Bateman, L-P. Boulet, H. A. Boushey, W. W. Busse, T. B. Casale, P. Chanez, P. L. Enright, P. G. Gibson, J. C. de Jongste, et al.
A new perspective on concepts of asthma severity and control
Eur. Respir. J., September 1, 2008; 32(3): 545 - 554.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al.
Global strategy for asthma management and prevention: GINA executive summary
Eur. Respir. J., January 1, 2008; 31(1): 143 - 178.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. L. James and S. Wenzel
Clinical relevance of airway remodelling in airway diseases
Eur. Respir. J., July 1, 2007; 30(1): 134 - 155.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
S. O Shaheen, R. B Newson, M. P Rayman, A. P-L Wong, M. K Tumilty, J. M Phillips, J. F Potts, F. J Kelly, P. T White, and P. G J Burney
Randomised, double blind, placebo-controlled trial of selenium supplementation in adult asthma
Thorax, June 1, 2007; 62(6): 483 - 490.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Vogelmeier, A. D'Urzo, R. Pauwels{dagger}, J. M. Merino, M. Jaspal, S. Boutet, I. Naya, and D. Price
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?
Eur. Respir. J., November 1, 2005; 26(5): 819 - 828.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. R. Jenkins, F. C. K. Thien, J. R. Wheatley, and H. K. Reddel
Traditional and patient-centred outcomes with three classes of asthma medication
Eur. Respir. J., July 1, 2005; 26(1): 36 - 44.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
G. P. Currie and D. K. C. Lee
The GOAL Study Designed to Favor a Long-acting {beta}2-Agonist?
Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 1060 - 1061.
[Full Text] [PDF]


Home page
Eur Respir JHome page
H.K. Reddel
Goals of asthma treatment: how high should we go?
Eur. Respir. J., November 1, 2004; 24(5): 715 - 717.
[Full Text] [PDF]


Home page
Evid. Based Med.Home page
F. Thien
Review: adults who require inhaled corticosteroids benefit from a moderate starting dose
Evid. Based Med., November 1, 2004; 9(6): 178 - 178.
[Full Text] [PDF]


Home page
ThoraxHome page
H K Reddel, G B Marks, and C R Jenkins
When can personal best peak flow be determined for asthma action plans?
Thorax, November 1, 2004; 59(11): 922 - 924.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
E. D. Bateman, H. A. Boushey, J. Bousquet, W. W. Busse, T. J. H. Clark, R. A. Pauwels, S. E. Pedersen, and for the GOAL Investigators Group
Can Guideline-defined Asthma Control Be Achieved?: The Gaining Optimal Asthma ControL Study
Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 836 - 844.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Masoli, M. Weatherall, S. Holt, and R. Beasley
From the authors:
Eur. Respir. J., September 1, 2004; 24(3): 513 - 514.
[Full Text] [PDF]


Home page
Eur Respir JHome page
M. Masoli, S. Holt, M. Weatherall, and R. Beasley
Dose-response relationship of inhaled budesonide in adult asthma: a meta-analysis
Eur. Respir. J., April 1, 2004; 23(4): 552 - 558.
[Abstract] [Full Text] [PDF]


Home page
Evid. Based Med.Home page
J. I Peters
Inhaled corticosteroids were safely stepped down in chronic, stable asthma
Evid. Based Med., January 1, 2004; 9(1): 16 - 16.
[Full Text] [PDF]


Home page
ThoraxHome page
C M Salome, J D Leuppi, R Freed, and G B Marks
Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation
Thorax, December 1, 2003; 58(12): 1042 - 1047.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S.T. Holgate, D. E. Davies, S. Puddicombe, A. Richter, P. Lackie, J. Lordan, and P. Howarth
Mechanisms of airway epithelial damage: epithelial-mesenchymal interactions in the pathogenesis of asthma
Eur. Respir. J., September 20, 2003; 22(44_suppl): 24s - 29s.
[Full Text] [PDF]


Home page
ThoraxHome page
D B Price, D Hernandez, P Magyar, J Fiterman, K M Beeh, I G James, S Konstantopoulos, R Rojas, J A van Noord, M Pons, et al.
Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
Thorax, March 1, 2003; 58(3): 211 - 216.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
A. L. James, P. S. Maxwell, G. Pearce-Pinto, J. G. Elliot, and N. G. Carroll
The Relationship of Reticular Basement Membrane Thickness to Airway Wall Remodeling in Asthma
Am. J. Respir. Crit. Care Med., December 15, 2002; 166(12): 1590 - 1595.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J-M. Ignacio-Garcia, M. Pinto-Tenorio, M.J. Chocron-Giraldez, F. Cabello-Rueda, A.I. Lopez-Cozar Gil, J-M. Ignacio-Garcia, and E. de Ramon-Garrido
Benefits at 3 yrs of an asthma education programme coupled with regular reinforcement
Eur. Respir. J., November 1, 2002; 20(5): 1095 - 1101.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
H K Reddel, G B Marks, C M Salome, C R Jenkins, C Ward, D Reid, and E H Walters
Inhaled corticosteroid dosage in asthma
Thorax, September 1, 2002; 57(9): 837 - 838.
[Full Text]


Home page
BMJHome page
H. K Reddel, B. G Toelle, G. B Marks, S. I Ware, C. R Jenkins, and A. J Woolcock
Analysis of adherence to peak flow monitoring when recording of data is electronic
BMJ, January 19, 2002; 324(7330): 146 - 147.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
C. M. SALOME, H. K. REDDEL, S. I. WARE, A. M. ROBERTS, C. R. JENKINS, G. B. MARKS, and A. J. WOOLCOCK
Effect of Budesonide on the Perception of Induced Airway Narrowing in Subjects with Asthma
Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 15 - 21.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. J. VISSER, D. S. POSTMA, L. R. ARENDS, T. W. DE VRIES, E. J. DUIVERMAN, and P. L. P. BRAND
One-Year Treatment with Different Dosing Schedules of Fluticasone Propionate in Childhood Asthma . Effects on Hyperresponsiveness, Lung Function, and Height
Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2073 - 2077.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
B. J. Lipworth, S. Edsbacker, L. P. Nielsen, and R. Dahl
THE PROBLEM OF DOSE-RESPONSE AND THERAPEUTIC RATIO OF INHALED STEROIDS
Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1758 - 1759.
[Full Text] [PDF]


Home page
JAMAHome page
S. T. Holgate
Therapeutic Options for Persistent Asthma
JAMA, May 23, 2001; 285(20): 2637 - 2639.
[Full Text] [PDF]


Home page
Eur Respir JHome page
E.D. Bateman, J. Bousquet, and G.L. Braunstein
Is overall asthma control being achieved? A hypothesis-generating study
Eur. Respir. J., April 1, 2001; 17(4): 589 - 595.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.